The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy
Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baselin...
Published in: | Arthritis Research & Therapy |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BioMed Central
2018
|
Subjects: | |
Online Access: | http://hdl.handle.net/10852/72752 http://urn.nb.no/URN:NBN:no-75832 https://doi.org/10.1186/s13075-018-1635-7 |
id |
ftoslouniv:oai:www.duo.uio.no:10852/72752 |
---|---|
record_format |
openpolar |
institution |
Open Polar |
collection |
Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
op_collection_id |
ftoslouniv |
language |
English |
description |
Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baseline ACPA reactivities in an inception cohort of patients with early RA, and to investigate their associations with disease activity, treatment response, ultrasound findings and radiographic damage. Methods: Disease-modifying antirheumatic drug (DMARD)-naïve patients with early RA, classified according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, were included in the ARCTIC trial and assessed in the present analysis. During follow up, patients were monitored frequently and treatment was adjusted according to a predetermined protocol, starting with methotrexate monotherapy with prednisolone bridging. Analysis of 16 different ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, filaggrin and histone was performed using a multiplex chip-based assay. Samples from 0, 3, 12 and 24 months were analysed. Controls were blood donors with similar characteristics to the patients (age, gender, smoking status). Results: A total of 217 patients and 94 controls were included. Median [25, 75 percentile] number of ACPA reactivities in all patients was 9 [4, 12], and were most prevalent in anti-cyclic citrullinated peptide /rheumatoid factor-positive patients 10 [7, 12]. Disease activity measures and ultrasound scores at baseline were lower in ACPA reactivity-positive compared to ACPA reactivity-negative patients. ACPA reactivity levels decreased after 3 months of DMARD treatment, most pronounced for fibrinogenβ 60–74 to 62% of baseline antibody level, with least change in filaggrin 307–324 to 81% of baseline antibody level, both p < 0.001. However, outcomes in disease activity measures, ultrasound and radiographic scores after 12 and 24 months were not associated with baseline levels or changes in ACPA reactivity levels and/or seroreversion after 3 months. Conclusions: The clinical relevance of analysing ACPA reactivities in intensively treated and closely monitored early RA was limited, with no apparent associations with disease activity, prediction of treatment response or radiographic progression. Further studies in larger patient materials are needed to understand the role of ACPA reactivities in patients with RA classified according to the 2010 ACR/EULAR criteria and treated according to modern treatment strategies. |
format |
Article in Journal/Newspaper |
author |
Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. |
spellingShingle |
Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
author_facet |
Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. |
author_sort |
Jonsson, Maria Karolina |
title |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_short |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_full |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_fullStr |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_full_unstemmed |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_sort |
role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
publisher |
BioMed Central |
publishDate |
2018 |
url |
http://hdl.handle.net/10852/72752 http://urn.nb.no/URN:NBN:no-75832 https://doi.org/10.1186/s13075-018-1635-7 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
1478-6362 |
op_relation |
http://urn.nb.no/URN:NBN:no-75832 Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. . The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. Arthritis Research & Therapy. 2018, 20 http://hdl.handle.net/10852/72752 1603450 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Arthritis Research & Therapy&rft.volume=20&rft.spage=&rft.date=2018 Arthritis Research & Therapy 20 1 11 https://doi.org/10.1186/s13075-018-1635-7 URN:NBN:no-75832 Fulltext https://www.duo.uio.no/bitstream/handle/10852/72752/1/ART_Jonsson_s13075-018-1635-7_2018.pdf |
op_rights |
Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/ |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.1186/s13075-018-1635-7 |
container_title |
Arthritis Research & Therapy |
container_volume |
20 |
container_issue |
1 |
_version_ |
1766349214443372544 |
spelling |
ftoslouniv:oai:www.duo.uio.no:10852/72752 2023-05-15T15:19:01+02:00 The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. 2018-08-21T11:09:53Z http://hdl.handle.net/10852/72752 http://urn.nb.no/URN:NBN:no-75832 https://doi.org/10.1186/s13075-018-1635-7 EN eng BioMed Central http://urn.nb.no/URN:NBN:no-75832 Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. . The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy. Arthritis Research & Therapy. 2018, 20 http://hdl.handle.net/10852/72752 1603450 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Arthritis Research & Therapy&rft.volume=20&rft.spage=&rft.date=2018 Arthritis Research & Therapy 20 1 11 https://doi.org/10.1186/s13075-018-1635-7 URN:NBN:no-75832 Fulltext https://www.duo.uio.no/bitstream/handle/10852/72752/1/ART_Jonsson_s13075-018-1635-7_2018.pdf Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/ CC-BY 1478-6362 Journal article Tidsskriftartikkel Peer reviewed PublishedVersion 2018 ftoslouniv https://doi.org/10.1186/s13075-018-1635-7 2020-06-21T08:53:20Z Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baseline ACPA reactivities in an inception cohort of patients with early RA, and to investigate their associations with disease activity, treatment response, ultrasound findings and radiographic damage. Methods: Disease-modifying antirheumatic drug (DMARD)-naïve patients with early RA, classified according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, were included in the ARCTIC trial and assessed in the present analysis. During follow up, patients were monitored frequently and treatment was adjusted according to a predetermined protocol, starting with methotrexate monotherapy with prednisolone bridging. Analysis of 16 different ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, filaggrin and histone was performed using a multiplex chip-based assay. Samples from 0, 3, 12 and 24 months were analysed. Controls were blood donors with similar characteristics to the patients (age, gender, smoking status). Results: A total of 217 patients and 94 controls were included. Median [25, 75 percentile] number of ACPA reactivities in all patients was 9 [4, 12], and were most prevalent in anti-cyclic citrullinated peptide /rheumatoid factor-positive patients 10 [7, 12]. Disease activity measures and ultrasound scores at baseline were lower in ACPA reactivity-positive compared to ACPA reactivity-negative patients. ACPA reactivity levels decreased after 3 months of DMARD treatment, most pronounced for fibrinogenβ 60–74 to 62% of baseline antibody level, with least change in filaggrin 307–324 to 81% of baseline antibody level, both p < 0.001. However, outcomes in disease activity measures, ultrasound and radiographic scores after 12 and 24 months were not associated with baseline levels or changes in ACPA reactivity levels and/or seroreversion after 3 months. Conclusions: The clinical relevance of analysing ACPA reactivities in intensively treated and closely monitored early RA was limited, with no apparent associations with disease activity, prediction of treatment response or radiographic progression. Further studies in larger patient materials are needed to understand the role of ACPA reactivities in patients with RA classified according to the 2010 ACR/EULAR criteria and treated according to modern treatment strategies. Article in Journal/Newspaper Arctic Universitet i Oslo: Digitale utgivelser ved UiO (DUO) Arctic Arthritis Research & Therapy 20 1 |